[HTML][HTML] Deep proteomic network analysis of Alzheimer's disease brain reveals alterations in RNA binding proteins and RNA splicing associated with disease
Background The complicated cellular and biochemical changes that occur in brain during
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …
Alzheimer's disease are poorly understood. In a previous study we used an unbiased label …
[HTML][HTML] Quantitative proteomics of cerebrospinal fluid from African Americans and Caucasians reveals shared and divergent changes in Alzheimer's disease
Background Despite being twice as likely to get Alzheimer's disease (AD), African
Americans have been grossly underrepresented in AD research. While emerging evidence …
Americans have been grossly underrepresented in AD research. While emerging evidence …
Phosphorylated tau-Aβ42 ratio as a continuous trait for biomarker discovery for early-stage Alzheimer's disease in multiplex immunoassay panels of cerebrospinal …
Background Identification of the physiologic changes that occur during the early stages of
Alzheimer's disease (AD) may provide critical insights for the diagnosis, prognosis, and …
Alzheimer's disease (AD) may provide critical insights for the diagnosis, prognosis, and …
[HTML][HTML] Deep multilayer brain proteomics identifies molecular networks in Alzheimer's disease progression
Alzheimer's disease (AD) displays a long asymptomatic stage before dementia. We
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
characterize AD stage-associated molecular networks by profiling 14,513 proteins and …
CSF proteome profiling across the Alzheimer's disease spectrum reflects the multifactorial nature of the disease and identifies specific biomarker panels
Abstract Development of disease-modifying therapies against Alzheimer's disease (AD)
requires biomarkers reflecting the diverse pathological pathways specific for AD. We …
requires biomarkers reflecting the diverse pathological pathways specific for AD. We …
Large‐scale plasma proteomic profiling identifies a high‐performance biomarker panel for Alzheimer's disease screening and staging
Introduction Blood proteins are emerging as candidate biomarkers for Alzheimer's disease
(AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers …
(AD). We systematically profiled the plasma proteome to identify novel AD blood biomarkers …
[HTML][HTML] Identification and validation of novel cerebrospinal fluid biomarkers for staging early Alzheimer's disease
RJ Perrin, R Craig-Schapiro, JP Malone, AR Shah… - PloS one, 2011 - journals.plos.org
Background Ideally, disease modifying therapies for Alzheimer disease (AD) will be applied
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
during the 'preclinical'stage (pathology present with cognition intact) before severe neuronal …
Cerebrospinal fluid and plasma biomarkers in Alzheimer disease
K Blennow, H Hampel, M Weiner… - Nature Reviews …, 2010 - nature.com
Intense multidisciplinary research has provided detailed knowledge of the molecular
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …
pathogenesis of Alzheimer disease (AD). This knowledge has been translated into new …
[HTML][HTML] Identification of longitudinally dynamic biomarkers in Alzheimer's disease cerebrospinal fluid by targeted proteomics
KR Wildsmith, SP Schauer, AM Smith, D Arnott… - Molecular …, 2014 - Springer
Background Alzheimer's disease (AD) is the leading cause of dementia affecting greater
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …
than 26 million people worldwide. Although cerebrospinal fluid (CSF) levels of Aβ 42, tau …
Targeted brain proteomics uncover multiple pathways to Alzheimer's dementia
Objective Previous gene expression analysis identified a network of coexpressed genes that
is associated with β‐amyloid neuropathology and cognitive decline in older adults. The …
is associated with β‐amyloid neuropathology and cognitive decline in older adults. The …